Gene Therapy For Neovascular AMD: Subretinal RGX-314: Phase I/IIa Long-Term Follow-Up Results Up To 4 Years
Peter Campochiaro M.D., Director, Retinal Cell and Molecular Laboratory, Professor of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine